TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24990578

Group type: EXPERIMENTAL
Intervention: New tuberculosis cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previously treated tuberculosis cases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with diabetes, ≥3 previous TB episodes, ≥1 significant regimen change, and MDR-TB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients aged ≥35, BMI <18.5, diabetes, and MDR-TB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cured cases at EOT with age ≥50 and BMI <18.5
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with treatment interruption
Number of subjects: 0
Study: 24990822

Group type: EXPERIMENTAL
Intervention: SSc patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PRP patients
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SSc and PRP patients
Number of subjects: 45
Study: 24990909

Group type: EXPERIMENTAL
Intervention: gE LIPS assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: viral capsid antigen ELISA
Number of subjects: 0

Group type: COMPARATOR
Intervention: glycoprotein ELISA
Number of subjects: 0
Study: 24990911

Group type: EXPERIMENTAL
Intervention: Influenza A(H1N1) vaccine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 122
Study: 24991041

Group type: EXPERIMENTAL
Intervention: 1 mg/d of folic acid (Pregnant Women)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0 mg/d of folic acid (Nonpregnant Women - NPW-0)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1 mg/d of folic acid (Nonpregnant Women - NPW-1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 5 mg/d of folic acid (Nonpregnant Women - NPW-5)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pregnant Women vs Nonpregnant Women
Number of subjects: 26
Study: 24991089

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Moderate-severe OSA (AHI > 5/hr TST)
Number of subjects: 204
Study: 24991142

Group type: EXPERIMENTAL
Intervention: Generic escitalopram
Number of subjects: 260

Group type: COMPARATOR
Intervention: Lexapro
Number of subjects: 260
Study: 24991893

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide + trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24992294

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg once daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg once daily with tenofovir
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg once daily without tenofovir
Number of subjects: 31
Study: 24992469

Group type: EXPERIMENTAL
Intervention: SSc-APAH
Number of subjects: 500

Group type: COMPARATOR
Intervention: non-SSc-CTD-APAH
Number of subjects: 500
Study: 24992948

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of 0.75 g L-alanine-L-glutamine for 24 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of 0.75 g L-alanine-L-glutamine for 5 days
Number of subjects: 12
Study: 24993487

Group type: EXPERIMENTAL
Intervention: Nestorone®/ethinyl estradiol contraceptive vaginal ring (CVR)
Number of subjects: 1036
Study: 24993530

Group type: EXPERIMENTAL
Intervention: Sebelipase alfa (1mg/kg or 3mg/kg) infused every-other-week
Number of subjects: 8
Study: 24993951

Group type: EXPERIMENTAL
Intervention: Custom graft designs
Number of subjects: 33

Group type: COMPARATOR
Intervention: Noncustom graft designs
Number of subjects: 33
Study: 24993987

Group type: EXPERIMENTAL
Intervention: Promus Element PtCr stents
Number of subjects: 337
Study: 24994545

Group type: EXPERIMENTAL
Intervention: Long-term statin pretreatment
Number of subjects: 795

Group type: COMPARATOR
Intervention: No statin pretreatment
Number of subjects: 795
Study: 24995780

Group type: EXPERIMENTAL
Intervention: Radiographic absence of both posterior communicating arteries (PCoAs)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Presence of at least 1 PCoA
Number of subjects: 38
Study: 24996510

Group type: EXPERIMENTAL
Intervention: tVNS (transcutaneous vagus nerve stimulation)
Number of subjects: 50
Study: 24996668

Group type: EXPERIMENTAL
Intervention: Adjudicated diagnosis of Acute Tubular Necrosis (ATN)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Adjudicated diagnosis of Pre-renal Azotemia (PRA)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Agreement among reviewers
Number of subjects: 475
Study: 24996765

Group type: EXPERIMENTAL
Intervention: Theory of Change (ToC) approach
Number of subjects: 0
Study: 24996961

Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details on intervention not available.
Number of subjects: 0
Study: 24997153

Group type: EXPERIMENTAL
Intervention: Deferasirox at a starting dose of 10 mg/kg/day for 52 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Deferasirox therapy continued
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Deferasirox therapy discontinued
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 30
Study: 24997328

Group type: EXPERIMENTAL
Intervention: Cytosponge
Number of subjects: 20

Group type: COMPARATOR
Intervention: Endoscopy
Number of subjects: 20
Study: 24997723

Group type: EXPERIMENTAL
Intervention: Noninvasive image-guided breast brachytherapy (NIBB)
Number of subjects: 40
Study: 24997880

Group type: EXPERIMENTAL
Intervention: Oral cysteamine bitartrate (60 mg/kg per day) and N-acetylcysteine (60 mg/kg per day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral cysteamine bitartrate and N-acetylcysteine
Number of subjects: 9
Study: 24999380

Group type: EXPERIMENTAL
Intervention: Rare variants of GABRB3 in patients with ASD
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Rare variants at the 5' regulatory region
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Reporter gene assays of rare variants
Number of subjects: 356

Group type: COMPARATOR
Intervention: Common SNPs
Number of subjects: 356
Study: 25000939

Group type: EXPERIMENTAL
Intervention: HPV infection
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: High-risk HPV types
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: HPV-16
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: HPV-18
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: HPV-31
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: HPV-45
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: HPV-52
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: HPV distribution by age
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: HPV-16/18 infection in ICC stage II or greater
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Single type infection
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Multiple infections
Number of subjects: 242
Study: 25001321

Group type: EXPERIMENTAL
Intervention: ranibizumab (0.5 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: bevacizumab (1.25 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: aflibercept (2.0 mg)
Number of subjects: 56
Study: 25001524

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m² i.v. Q3W plus oral prednisone/prednisolone 10 mg daily
Number of subjects: 153
Study: 25002028

Group type: EXPERIMENTAL
Intervention: Combination of CDK 4/6 inhibitors and PI3K inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent PI3K inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: PI3K inhibitor BYL719
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of PI3K and CDK 4/6 inhibitors
Number of subjects: 0
Study: 25002194

Group type: EXPERIMENTAL
Intervention: Access to asthma/COPD clinics
Number of subjects: 21361
Study: 25002964

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Lactobacillus reuteri
Number of subjects: 61
Study: 25003275

Group type: EXPERIMENTAL
Intervention: Six-Minute Step Test (6MST)
Number of subjects: 32
Study: 25003311

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery system; subjects received three mixed meals (1 g of carbohydrate/kg of body weight; 100 g maximum) with meal announcement and automated insulin dosing.
Number of subjects: 53
Study: 25003359

Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY720, Gilenya), 0.5 mg, orally for 3 consecutive days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY720, Gilenya)
Number of subjects: 23
Study: 25004134

Group type: EXPERIMENTAL
Intervention: Outpatients (FLU 002)
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Inpatients (FLU 003)
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: ICU patients
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: General ward patients
Number of subjects: 982
Study: 25004340

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Copper-releasing intrauterine device
Number of subjects: 165
Study: 25004404

Group type: EXPERIMENTAL
Intervention: Plasma 25-hydroxyvitamin D3 (25(OH)D3)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Plasma 3-epi-25-hydroxyvitamin D3 (3-epi-25(OH)D3)
Number of subjects: 132
Study: 25004466

Group type: EXPERIMENTAL
Intervention: CoDuSe program (balance exercise program)
Number of subjects: 32
Study: 25005255

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab with chemotherapy
Number of subjects: 0
Study: 25005444

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.4 μg/kg IV
Number of subjects: 14
Study: 25005721

Group type: EXPERIMENTAL
Intervention: New or worsened diastolic dysfunction (DD) after CPB
Number of subjects: 109

Group type: COMPARATOR
Intervention: Unchanged or improved diastolic dysfunction (DD) after CPB
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Age ≥65 years
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: New or worsened diastolic dysfunction (DD)
Number of subjects: 109
Study: 25006228

Group type: EXPERIMENTAL
Intervention: UUI cohort
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-UUI cohort
Number of subjects: 0
Study: 25006744

Group type: EXPERIMENTAL
Intervention: Genome-wide association studies (GWAS) for emphysema patterns
Number of subjects: 9614

Group type: EXPERIMENTAL
Intervention: Enhancer enrichment analysis for top GWAS associations
Number of subjects: 9614
Study: 25006795

Group type: EXPERIMENTAL
Intervention: Born outside the United States
Number of subjects: 2786

Group type: EXPERIMENTAL
Intervention: Born outside the United States and residing inside the United States
Number of subjects: 2786

Group type: EXPERIMENTAL
Intervention: Born outside the United States and residing outside the United States
Number of subjects: 2786

Group type: EXPERIMENTAL
Intervention: Birthplace in all continents
Number of subjects: 2786

Group type: EXPERIMENTAL
Intervention: Latitude closer to the equator
Number of subjects: 2786
Study: 25007130

Group type: EXPERIMENTAL
Intervention: AZD8931 ([(14)C]-AZD8931) administered orally or intravenously; dosage not specified; single doses.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD8931 metabolism in rats; specific metabolic pathways not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD8931 metabolism in dogs; specific metabolic pathways not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD8931 metabolism in humans; specific metabolic pathways not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD8931 excretory profiles in humans; specific metabolites not detailed.
Number of subjects: 0
Study: 25007364

Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 25007707

Group type: EXPERIMENTAL
Intervention: Physician Engagement scale
Number of subjects: 4266

Group type: EXPERIMENTAL
Intervention: Teamness scale
Number of subjects: 4266

Group type: EXPERIMENTAL
Intervention: Team Effectiveness scale
Number of subjects: 4266
Study: 25007944

Group type: EXPERIMENTAL
Intervention: Imatinib 200 mg/day for 6 months
Number of subjects: 30
Study: 25008852

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D) levels across different latitudes
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D) levels in Ghana
Number of subjects: 2500
Study: 25008855

Group type: EXPERIMENTAL
Intervention: Good financial planning skills and low delay discounting
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Good financial planning skills and high delay discounting
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: High food insecurity with good financial planning skills and low delay discounting
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: High food insecurity with good financial planning skills and high delay discounting
Number of subjects: 975
Study: 25008856

Group type: EXPERIMENTAL
Intervention: Provided diet containing 6-cup equivalents (1046 g/d) of vegetables and fruit (8 wk, phase 2)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-carotenoid diets (6 wk, phases 1 and 3)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual diet (final 8 wk, phase 4)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Skin carotenoid status assessed by resonance Raman spectroscopy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Skin and plasma carotenoid values correlation
Number of subjects: 29
Study: 25008917

Group type: EXPERIMENTAL
Intervention: HIV-1 gp140 linked to HSP70 administered vaginally
Number of subjects: 0
Study: 25009010

Group type: EXPERIMENTAL
Intervention: AKT inhibitor treatment during the fourth line of therapy
Number of subjects: 1
Study: 25009013

Group type: EXPERIMENTAL
Intervention: Induction therapy with cetuximab, paclitaxel, and carboplatin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT) with cetuximab, paclitaxel, and carboplatin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Induction therapy with cetuximab, paclitaxel, and carboplatin followed by CRT
Number of subjects: 63
Study: 25009225

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study: 25009371

Group type: EXPERIMENTAL
Intervention: Albumin dialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies with albumin dialysis
Number of subjects: 0
Study: 25010170

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0
Study: 25010745

Group type: EXPERIMENTAL
Intervention: Magnesium at 2.5 mmol/l
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Magnesium at 1 mmol/l
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 20
Study: 25011615

Group type: EXPERIMENTAL
Intervention: Epoetin zeta (median dose 30,000 IU/week)
Number of subjects: 2333
Study: 25011656

Group type: EXPERIMENTAL
Intervention: 600 mg linezolid intravenously twice a day
Number of subjects: 30
Study: 25011943

Group type: EXPERIMENTAL
Intervention: Overfeeding (40% more than baseline requirement for 8 weeks)
Number of subjects: 29
Study: 25011951

Group type: EXPERIMENTAL
Intervention: Glycation of the α-chain (Glα) in neonates from GDM
Number of subjects: 67

Group type: COMPARATOR
Intervention: Glycation of the α-chain (Glα) in neonates from NGT
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Correlation of Glα with maternal A1C in overall cohort
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Correlation of Glα with maternal A1C in GDM group
Number of subjects: 67

Group type: COMPARATOR
Intervention: Correlation of Glα with maternal A1C in NGT group
Number of subjects: 67
Study: 25012414

Group type: EXPERIMENTAL
Intervention: Brief Assessment of Cognition in Affective Disorder (BAC-A)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Affective Processing Test
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Composite score combining six core cognitive subtests of BAC-A and two measures from the Affective Processing Test
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Traditional cognitive tests
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Affective Processing Test measures
Number of subjects: 432
Study: 25012943

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 12
Study: 25012994

Group type: EXPERIMENTAL
Intervention: Caucasian smokers
Number of subjects: 1672

Group type: COMPARATOR
Intervention: African American smokers
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: Female smokers
Number of subjects: 1672

Group type: COMPARATOR
Intervention: Male smokers
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: Birth control pill users (females)
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy users (females)
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: Cigarette consumption
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: Mentholated cigarette users
Number of subjects: 1672
Study: 25013718

Group type: EXPERIMENTAL
Intervention: Serial monitoring of IL-6 and CRP levels using a bedside micro sample test device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequent biomarker monitoring
Number of subjects: 0
Study: 25013998

Group type: EXPERIMENTAL
Intervention: Mifepristone (300-1200 mg) administered once daily
Number of subjects: 43
Study: 25015089

Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m²) single-dose 2-3 hours before surgery
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lapatinib (1250 mg) daily for 2-5 doses, last dose 2-3 hours before surgery
Number of subjects: 12
Study: 25015177

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention including high exercise volume (15-20 h/week), restrictive diet (-500 kcal/day), and education
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study: 25015202

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation with weekly paclitaxel (60 mg/m² administered once weekly for 5 weeks during radiation therapy)
Number of subjects: 57
Study: 25015413

Group type: EXPERIMENTAL
Intervention: 75 g oral glucose tolerance test (OGTT) using IADPSG criteria
Number of subjects: 2563

Group type: EXPERIMENTAL
Intervention: 50 g glucose challenge test (GCT)
Number of subjects: 2563

Group type: EXPERIMENTAL
Intervention: Standardized routine care protocol for diabetes and GDM treatment
Number of subjects: 2563
Study: 25015575

Group type: EXPERIMENTAL
Intervention: Hepato-portoenterostomy (HPE) surgery
Number of subjects: 219
Study: 25015938

Group type: EXPERIMENTAL
Intervention: Bortezomib, melphalan, and prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib, melphalan, prednisone, and thalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib and thalidomide maintenance
Number of subjects: 0
Study: 25016003

Group type: EXPERIMENTAL
Intervention: Imexon (1000 mg/m² IV daily for 5 days in 21-day cycles)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Imexon
Number of subjects: 22
Study: 25016127

Group type: EXPERIMENTAL
Intervention: Intravenous hematin
Number of subjects: 108
Study: 25016368

Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) treatment according to national guidelines
Number of subjects: 350

Group type: COMPARATOR
Intervention: Non-OSA subjects
Number of subjects: 350
Study: 25016482

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily)
Number of subjects: 17
Study: 25016924

Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg intravenously every 2 weeks)
Number of subjects: 60
Study: 25018070

Group type: EXPERIMENTAL
Intervention: Severe asthma
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All subjects (including severe asthma, mild-to-moderate asthma, and normals)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Baseline WA%, race, and health care utilization
Number of subjects: 38
Study: 25018648

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 200 mg/day
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 400 mg/day
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study: 25018650

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine-based multimodal analgesia
Number of subjects: 191

Group type: COMPARATOR
Intervention: IV opioid PCA
Number of subjects: 191
Study: 25018910

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived, culture-expanded allogeneic mesenchymal stem cells administered into the suprarenal aorta after reflow.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle-treated controls
Number of subjects: 0
Study: 25019562

Group type: EXPERIMENTAL
Intervention: Myocardial scar group
Number of subjects: 429

Group type: COMPARATOR
Intervention: T1 time 12 minutes after contrast material injection
Number of subjects: 429

Group type: COMPARATOR
Intervention: T1 time 25 minutes after contrast material injection
Number of subjects: 429
Study: 25019647

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 7248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7248
Study: 25020262

Group type: EXPERIMENTAL
Intervention: Sodium selenite in a continual infusion of 750μg/24h for 6 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 25022285

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5-20 mg/day
Number of subjects: 43
Study: 25022447

Group type: EXPERIMENTAL
Intervention: Sputum Induction (SI)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Early morning expectorated sputum
Number of subjects: 555
Study: 25022596

Group type: EXPERIMENTAL
Intervention: ART (tenofovir/emtricitabine/efavirenz, with ritonavir/lopinavir substitution for efavirenz available)
Number of subjects: 197